Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel
HrQoL remained stable during and after therapy. Female gender and disease progression negatively impacted HrQoL. The development of irAEs was not associated with HrQoL, though this may not apply to severe irAEs like colitis, which were not assessed.
Authors
- Christine Blome (ORCID: https://orcid.org/0000-0002-1163-1639)
- Katharina C. Kähler (ORCID: https://orcid.org/0000-0001-9953-0893)
- Ann‐Sophie Bohne (ORCID: https://orcid.org/0000-0003-3234-4281)
- Carolin Grote
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s00432-024-05981-2
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.26